Clearmind Medicine (CMND) Competitors $1.03 +0.01 (+0.98%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.01 -0.02 (-2.14%) As of 08/15/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMND vs. BLRX, MTEX, EDSA, GELS, CYCC, BTAI, ALLR, LPTX, CTXR, and TRIBShould you be buying Clearmind Medicine stock or one of its competitors? The main competitors of Clearmind Medicine include BioLineRx (BLRX), Mannatech (MTEX), Edesa Biotech (EDSA), Gelteq (GELS), Cyclacel Pharmaceuticals (CYCC), BioXcel Therapeutics (BTAI), Allarity Therapeutics (ALLR), Leap Therapeutics (LPTX), Citius Pharmaceuticals (CTXR), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. Clearmind Medicine vs. Its Competitors BioLineRx Mannatech Edesa Biotech Gelteq Cyclacel Pharmaceuticals BioXcel Therapeutics Allarity Therapeutics Leap Therapeutics Citius Pharmaceuticals Trinity Biotech Clearmind Medicine (NASDAQ:CMND) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Does the media favor CMND or BLRX? In the previous week, BioLineRx had 6 more articles in the media than Clearmind Medicine. MarketBeat recorded 8 mentions for BioLineRx and 2 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 1.44 beat BioLineRx's score of 0.04 indicating that Clearmind Medicine is being referred to more favorably in the media. Company Overall Sentiment Clearmind Medicine Positive BioLineRx Neutral Is CMND or BLRX more profitable? Clearmind Medicine has a net margin of 0.00% compared to BioLineRx's net margin of -45.34%. BioLineRx's return on equity of -54.79% beat Clearmind Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Clearmind MedicineN/A -164.79% -71.12% BioLineRx -45.34%-54.79%-17.36% Which has better valuation & earnings, CMND or BLRX? Clearmind Medicine has higher earnings, but lower revenue than BioLineRx. Clearmind Medicine is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearmind MedicineN/AN/A-$5.26M-$1.10-0.94BioLineRx$28.94M0.55-$9.22M-$8.80-0.42 Do analysts recommend CMND or BLRX? BioLineRx has a consensus target price of $26.00, indicating a potential upside of 600.81%. Given BioLineRx's stronger consensus rating and higher possible upside, analysts plainly believe BioLineRx is more favorable than Clearmind Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clearmind Medicine 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do insiders & institutionals believe in CMND or BLRX? 96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, CMND or BLRX? Clearmind Medicine has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. SummaryBioLineRx beats Clearmind Medicine on 11 of the 16 factors compared between the two stocks. Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMND vs. The Competition Export to ExcelMetricClearmind MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.35M$2.76B$5.69B$9.81BDividend YieldN/A1.77%3.79%4.07%P/E Ratio-0.9422.1831.0825.11Price / SalesN/A739.41466.03115.16Price / CashN/A177.1637.4059.05Price / Book1.415.079.096.18Net Income-$5.26M$31.61M$3.26B$265.11M7 Day Performance4.36%25.12%7.31%4.20%1 Month Performance5.10%3.84%5.43%2.00%1 Year Performance-9.65%10.43%30.60%23.76% Clearmind Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMNDClearmind Medicine1.0652 of 5 stars$1.03+1.0%N/A-9.6%$4.35MN/A-0.94N/APositive NewsShort Interest ↓BLRXBioLineRx3.3191 of 5 stars$3.89+1.3%$26.00+568.4%-86.3%$16.37M$28.94M-0.4440News CoverageEarnings ReportAnalyst RevisionMTEXMannatech0.4523 of 5 stars$7.99-5.3%N/A+25.3%$16.04M$117.87M-79.90250News CoverageEarnings ReportShort Interest ↑Gap DownEDSAEdesa Biotech2.1052 of 5 stars$2.21-2.6%$5.00+126.1%-48.4%$15.92MN/A-1.3920Earnings ReportShort Interest ↓Analyst RevisionGELSGelteqN/A$1.66-0.6%N/AN/A$15.76M$100K0.00N/ACYCCCyclacel Pharmaceuticals1.2693 of 5 stars$8.21-16.3%N/A-97.5%$15.55M$40K-0.0114News CoveragePositive NewsEarnings ReportAnalyst UpgradeBTAIBioXcel Therapeutics4.5308 of 5 stars$2.97+16.9%$42.60+1,334.3%-49.6%$15.38M$2.27M-0.2290News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Gap DownHigh Trading VolumeALLRAllarity Therapeutics3.4047 of 5 stars$1.04+3.0%$9.00+765.4%-80.3%$15.23MN/A0.0010News CoverageEarnings ReportUpcoming EarningsLPTXLeap Therapeutics2.4003 of 5 stars$0.33-8.3%$3.38+925.8%-89.1%$14.86MN/A-0.1940News CoverageEarnings ReportShort Interest ↓Gap UpHigh Trading VolumeCTXRCitius Pharmaceuticals2.8772 of 5 stars$1.35-2.9%$53.00+3,825.9%-90.9%$14.78MN/A0.0020News CoverageEarnings ReportAnalyst ForecastShort Interest ↓Gap UpTRIBTrinity Biotech1.4857 of 5 stars$0.90+10.0%N/A-29.6%$14.77M$61.56M-0.31480News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies BLRX Competitors MTEX Competitors EDSA Competitors GELS Competitors CYCC Competitors BTAI Competitors ALLR Competitors LPTX Competitors CTXR Competitors TRIB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMND) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access